Cetuximab, its clinical use and future perspectives

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Elevated expression of epidermal growth factor receptors (EGFR) is common in various cancers.
• EGFR overexpression is linked to advanced disease, poor prognosis, and reduced chemotherapy effectiveness.
• Targeting EGFR presents a viable strategy for cancer therapy.

Purpose of the Study:

• To review the current and future applications of monoclonal antibodies against EGFR.
• To focus on cetuximab, a prominent EGFR-targeting antibody.
• To examine cetuximab's research and clinical development in various cancers, especially colorectal cancer.

Main Methods:

• Review of existing literature on EGFR-targeting monoclonal antibodies.
• Focus on clinical studies and research involving cetuximab.
• Analysis of cetuximab's efficacy in colorectal, head and neck, lung, pancreatic, gastric, oesophageal, ovarian cancers, and malignant gliomas.

Main Results:

• Monoclonal antibodies targeting the extracellular domain of EGFR are a key therapeutic approach.
• Cetuximab has been extensively studied, particularly in colorectal cancer.
• Cetuximab demonstrates clinical relevance in head and neck, lung, and other solid tumors.

Conclusions:

• EGFR inhibition via monoclonal antibodies, like cetuximab, is a significant advancement in cancer treatment.
• Cetuximab shows promise across a spectrum of malignancies, with substantial data in colorectal cancer.
• Further research and clinical application of EGFR-targeting antibodies are anticipated.